Impact of Neutrophil Activation in Acute Ischemic Stroke Patients Treated With Endovascular Therapy
NCT ID: NCT02900833
Last Updated: 2026-01-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
440 participants
OBSERVATIONAL
2016-03-24
2026-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The objective is to study the time dependent impact of neutrophils in AIS and the predominant mediators in each time point to identify the appropriate therapeutic target and time window.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Impact of Neutrophil Extracellular Traps on Tissue Plasminogen Activator Induced Thrombolysis in Acute Ischemic Stroke Patients
NCT02907736
Neutrophil Extracellular Traps and Thrombolysis in the Acute Stroke
NCT02476188
Evaluation of IL-33 in Patients With the Acute Ischemic Stroke
NCT03948802
Effect of Natalizumab on Infarct Volume in Acute Ischemic Stroke
NCT01955707
Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke
NCT02730455
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
CROSS_SECTIONAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* acute ischemic stroke secondary to a large vessel occlusion.
* Patients hospitalized for endovascular therapy.
Exclusion Criteria
* patient under legal protection
* Patient opposition to participate in this study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fondation Ophtalmologique Adolphe de Rothschild
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jean-Philippe DESILLES, MD
Role: PRINCIPAL_INVESTIGATOR
Fondation OPH A de Rothschild
Mikael MAZIGHI, MD, PhD
Role: STUDY_CHAIR
Fondation OPH A de Rothschild
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fondation Ophtalmologique Adolphe de Rothschild
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Boutelier A, Ollivier V, Mazighi M, Kyheng M, Labreuche J, Brikci-Nigassa N, Solo Nomenjanahary M, Delvoye F, Maier B, Paquet C, Ho-Tin-Noe B, Desilles JP. Acute astrocytic reaction is associated with 3-month functional outcome after stroke treated with endovascular therapy. Eur Stroke J. 2024 Dec;9(4):952-958. doi: 10.1177/23969873241256813. Epub 2024 Jun 6.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
JDS_2015_46
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.